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ABSTRACT
Objective: A conceptual framework for patient-reported outcomes
(PROs) is a structured representation of outcome concepts and issues. Our
aim was to develop a conceptual framework of PROs for hormone-
refractory prostate cancer (HRPC) to support measurement clarity.
Methods: Relevant outcome issues were identiﬁed from review of recent
clinical trials. This provided content for an interview with 15 metastatic
HRPC patients and a survey of 10 practitioners. All participants were asked
about the relevance and importance of 26 outcomes and were allowed to
nominate new outcomes. Practitioners were also asked to determine which
outcomes endorsed by patients were attributable to the disease (symptoms)
versus treatment (side effects). Analyses of archived clinical trial data were
used to verify and augment the interview and survey results.
Results: Patients endorsed 11 concerns as relevant and important to
HRPC including general pain, bone pain, urinary problems, fatigue,
appetite loss, constipation, erectile dysfunction, peripheral neuropathy,
diarrhea, PSA anxiety, and changes in self image. Practitioner judgments
helped classify each concern into one of four categories, disease symptom,
treatment side effect, both symptom and side effect, or psychological
concern. Additionally, patients endorsed (and practitioners conﬁrmed) the
relevance and importance of several general domains of quality of life.
Analyses of archived data conﬁrmed the importance of these issues and
suggested two additional concerns.
Conclusion: Findings were used to propose a conceptual framework of
PROs for metastatic HRPC. Such frameworks can be used to help specify
targets for assessment in clinical studies such as treatment trials.
Keywords: conceptual framework, hormone-refractory, patient-reported
outcomes, prostate cancer, quality of life.
Introduction
In oncology treatment trials of new medical products, traditional
clinical outcomes such as survival, time to disease progression,
and objective responses to treatment are usually considered the
“gold standards” for determining treatment effectiveness.
However, these are not the only outcomes of relevance to
patients. Disease symptoms, treatment side effects, functional
status, and health-related quality of life (HRQL) are also critical
issues to assess when determining the overall impact of therapy
on patient well-being. Today, clinical researchers are incorporat-
ing patient self-report outcomes into clinical trials with increas-
ing regularity in order to determine not only the objective
physiological beneﬁts of treatment, but also how patients subjec-
tively feel and function after therapy [1]. These “patient-reported
outcomes” include subjective assessments made by the patient
regarding various elements of their health including: symptoms,
function, well-being, HRQL, and perceptions about treatment
[2].
Patient-reported outcomes (PROs) are typically assessed
using questionnaires or surveys administered directly to patients.
Although PROs have been used as end points in clinical trials for
decades, recent regulatory concern over the validity of existing
questionnaires has received attention. Speciﬁcally, the U.S. Food
& Drug Administration (FDA) published a draft guidance docu-
ment to inform industry sponsors, clinicians, and researchers on
how to develop and use PRO measures to support beneﬁt claims
that could potentially be used in product labeling [3]. The guid-
ance summarizes a four-step process by which PROs should be
developed, validated, and modiﬁed to receive a product label
claim. All of these steps must be carefully considered and fully
documented by the sponsor intending to use a PRO instrument in
a clinical trial, regardless of whether the sponsor intends to
develop a new instrument, use an existing instrument (or battery
of instruments), or modify an existing instrument [1]. The ﬁrst
step in this process involves the articulation of a conceptual
framework of subjective patient-relevant outcomes [3].
A conceptual framework is a diagram of the expected rela-
tionships between speciﬁc outcome issues (e.g., items in a PRO
instrument) and the overall concepts measured by the instrument
and represented as scores [2,3]. Some have referred to the con-
ceptual framework as a content map or measurement model [4].
Practically speaking, the framework should answer two key
questions. First, what are the principal outcome issues for a given
health context, and second, how can these outcome issues be
grouped or classiﬁed into concepts (i.e., domains)? A well-
deﬁned conceptual framework of relevant outcomes is critical
because it can justify the use of an existing PRO instrument or
the development of a new or modiﬁed PRO instrument to
support a desired label claim [1]. An inappropriately articulated
framework can hinder instrument development as well as the
scoring, analysis, and interpretation of PRO data, thus jeopar-
dizing the ability of the PRO ﬁndings to be supportive of the
target claim [2]. In short, the conceptual framework provides the
foundation on which any PRO beneﬁt claim will ultimately rest.
Although there is no standard methodology for constructing
a conceptual framework, most researchers rely on an approach
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that combines multiple sources of data. Literature review is often
used to summarize relevant outcome issues germane to the health
condition under study [4,5]. This can include identiﬁcation of
disease symptoms, side effects of current treatments, and impacts
on general HRQL. Reviews of the clinical treatment literature
can also help identify existing PRO instruments that may further
elucidate important outcomes as well as specify measures that
might be used to assess those outcomes in a trial. Patient input is
considered vital to the construction of a conceptual framework.
Typically, focus groups or qualitative interviews are used to
solicit feedback on patients’ subjective experience of a given
health condition [4–6]. Input from key opinion leaders such as
practitioners and other ﬁeld experts can modify and elaborate the
input of patients [4,6]. Ideally, the conceptual framework is
constructed using both qualitative and quantitative methods with
reliance on multiple sources of information. The process is itera-
tive and can evolve over time as new information about the
patient’s experience of the health condition and its treatment
become available [1,2,4].
In support of a clinical trials’ program in hormone-refractory
prostate cancer (HRPC), we set out to build a conceptual frame-
work of relevant outcome issues for men with this disease. Pros-
tate cancer is the most commonly diagnosed non-skin cancer in
men and the second leading cause of cancer death [7]. Most men
are initially diagnosed with early-stage or clinically localized
disease. Treatments for clinically localized prostate cancer
usually involve early intervention with surgery, radiotherapy,
androgen deprivation, or observation [8]. However, almost 10%
of men are initially diagnosed with advanced-stage disease, and
many others will develop advanced and metastatic disease
despite treatment with surgery or radiotherapy [8]. To stem the
spread of disease, patients with advanced prostate cancer are
typically treated with primary androgen ablation (via surgical or
medical castration with or without anti-androgens). Eventually,
most men will become refractory to these hormonal treatments
[9]. Treatment options for men with HRPC include chemo-
therapy, secondary hormonal manipulation, radiotherapy (to
bones), and radioisotope therapy [10]. Prior to 2005, the goal of
all of these treatments was symptom palliation, especially relief
of pain from bone metastases. This changed with the publication
of two Phase III clinical trials, demonstrating a survival beneﬁt in
HRPC patients treated with docetaxel-based chemotherapy
[11,12]. In TAX 327, docetaxel-based chemotherapy also
resulted in signiﬁcant reductions in pain and improvements in
overall HRQL compared to standard mitoxantrone-based che-
motherapy [11]. Although these clinical ﬁndings were supportive
of regulatory approval of docetaxel-based chemotherapy, the
increased survival beneﬁt observed in both studies was modest
(<2.5 months). Hence, today’s clinical trialists are investigating
agents that could improve upon the survival and symptom pal-
liation beneﬁts of docetaxel while maintaining an acceptable
toxicity proﬁle. Developing a conceptual framework of PROs
will be an important adjunct to these trials because it can help
clarify the most critical patient-relevant outcome issues to assess.
The objective of this study was to derive a conceptual framework
of PROs for HRPC using methods consistent with the FDA
Guidance and current expert opinion [3,4].
Overview
We combined information extracted from the published litera-
ture with input from patients and experts along with independent
veriﬁcation using analyses of archival data. The ﬂow of work
appears in Figure 1. Because each step builds upon the results of
a prior step, we will discuss the methods and results of each step
separately, leading to the ﬁnal proposed conceptual framework.
Initial concept ID
- Literature review 
Patient input
- Interview 
Expert input
- Survey 
Compile & Analyze Patient & Expert Data 
Create Preliminary Conceptual Framework 
Analyze available 
archived data of 
HRPC patients
- Modify framework 
Propose Final 
Conceptual Framework 
Step 1 
Step 2 
Step 3 
Figure 1 Methods overview and ﬂow of work.
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Methods of Step 1—Literature Review
The objective of step 1 was to identify symptoms, complications,
toxicities, and HRQL issues associated with advanced HRPC
and its treatment. A literature search was conducted to identify
the most recently completed randomized clinical trials in HRPC.
The search was limited to those trials conducted from 2004, the
year in which the two pivotal phase III trials of docetaxel were
published (TAX 327 and SWOG 9916) [11,12]. From this litera-
ture search, several recently conducted systematic reviews of the
treatment literature were also identiﬁed. Reviews dating from
2006 were selected to focus on patient outcome issues relevant to
the most current standards of treatment.
Search strategy and study eligibility. Two databases were
searched, MEDLINE and the Cochrane Register of Controlled
Clinical Trials, from 2004 through 2007 (note: the search and
review were commenced and completed in January, 2008). The
following keywords were used in the search: (prostate cancer OR
prostatic neoplasms) AND (hormone-refractory OR androgen-
independent OR hormone-resistant) AND (symptom* OR
quality of life OR Toxicit*) AND (random* OR clinical OR
trial). The MEDLINE search yielded a total of 259 unique cita-
tions. Although 32 citations were uncovered from the search of
the Cochrane database, all had already been identiﬁed in the
MEDLINE search. Citation abstracts were reviewed; and the
complete article was retrieved if the study was either, 1) a ran-
domized clinical trial (or nonrandomized, but controlled trial) of
men treated for HRPC with at least 50 patients per treatment
arm; or 2) a prospective, uncontrolled study enrolling at least
200 men with HRPC. Only studies that used PROs as outcomes
were eligible for review. For instance, studies using HRQL as a
predictor of other clinical outcomes were excluded. Using these
criteria we selected 24 studies for review of PROs such as symp-
toms, treatment side effects/toxicities, and HRQL domains. We
also identiﬁed ﬁve reviews of the recent clinical treatment litera-
ture (2006–07) that referenced important data on symptoms,
side effects/toxicities, and HRQL. All were structured, systematic
literature reviews of randomized trials and/or clinical studies
each led by either a formal review group [9,13,14], an outcomes
measurement expert [15], or a physician expert [16].
Results of Step 1
Because the objective of this task was to identify outcome issues
that could form the basis for interview and survey queries of
patients and practitioners, attention was focused exclusively on
extracting information about patient-relevant outcomes such as
symptoms, side effects/toxicities, and HRQL. Regarding the
clinical studies literature (clinical trials and large-scale prospec-
tive, observational studies), data were extracted on baseline (pre-
treatment) symptoms of disease, changes in symptoms and
HRQL over time, and treatment side effects/toxicities. Outcome
issues were extracted for later query if: 1) they were frequently
observed prior to treatment (e.g., notably heightened at baseline
or used as stratiﬁcation criteria); 2) they were found to change
over time in multiple studies or study arms; or 3) they repre-
sented frequently occurring side effects or toxicities (e.g., any
grade toxicity occurring 50%) or were severe and noticeable
(e.g., a grade 3 or 4 toxicity occurring 10%). Findings from
reviews of the treatment literature were used mainly to corrobo-
rate the ﬁndings from clinical studies; however, any salient new
outcome issues could also be highlighted for later query.
PROs in clinical studies and reviews. Among the clinical studies
pain was the most frequently observed symptom at baseline.
Pain was heightened at baseline in 7 of 22 studies (note: two
studies were HRQL analyses from SWOG 9916) [17,18]. More
speciﬁcally, bone pain was reportedly heightened at baseline in
3 of 22 studies. In the two pivotal trials of docetaxel, TAX 327
and SWOG 9916, self-reported pain was used to stratify
patients prior to randomization [11,12]. Table 1 provides fre-
quency counts of the number of times certain PROs were found
to have changed over time (per treatment arm). Clinical reviews
of the treatment literature veriﬁed the relevance of many of
these same PROs (including, prostate cancer-speciﬁc concerns,
pain, general quality of life, physical, role, and emotional func-
tion). Additionally, constipation was reportedly improved in
some trials of chemotherapy [13]. Those concerns/domains that
appear more than once in clinical studies or were highlighted in
clinical reviews were marked for later query with patients and
practitioners.
Side effects and toxicities in clinical studies and reviews. Treat-
ment side effects or toxicities were selected from clinical studies
if they met at least one of the following criteria: 1) it was
observed in any study arm at a rate 50% (any grade), OR 2) it
was severe (i.e., grade 3 or 4) and was observed in a study arm at
a rate 10%. The most frequently reported side effect/toxicities
included fatigue and nausea/vomiting; however, alopecia,
gynecomastia, infection, pain, bone pain, and diarrhea were also
reported more than once (see Table 2). Toxicities based on clini-
cal chemistry (i.e., hematologic toxicities) were noted, but not
further considered because the objective was to identify outcome
issues that rely exclusively on patient self-report.
Clinical reviews of the treatment literature veriﬁed the rel-
evance of nausea/vomiting and diarrhea with both being associ-
ated with more than one drug treatment for HRPC. A review of
the epothilones [16] identiﬁed peripheral neuropathy (tingling in
the hands and feet) as a frequently occurring toxicity. Hence, this
was added to the list of issues for later patient and practitioner
query. Overall, a total of 22 outcome issues were marked for later
query including the following: fatigue, nausea, vomiting, diar-
rhea, constipation, other bowel problems, hair loss, breast
enlargement, infections, pain (in general), bone pain, peripheral
neuropathy, appetite loss, weight loss, urinary obstruction/
frequency, erectile dysfunction, masculine self-image, physical
function, emotional distress, functional well-being, social func-
tion, and global quality of life.
Table 1 Patient-reported outcomes showing change in HRPC clinical
studies (no. of times identiﬁed per treatment arm)
Concern or domain Count
Pain 10
Prostate Cancer-speciﬁc concerns (PCS)* 9
Global QOL 8
Emotional function 5
General QOL (total scores of measure—ie., FACT-P)** 5
Fatigue 4
Physical function 4
Nausea/vomiting 3
Analgesic use 2
Functional well-being/role function 2
Depression 1
Appetite 1
*Prostate cancer subscale (PCS) of the FACT-P. Consists of 12 items assessing: pain-4, weight
loss-1, appetite-1, masculine image-1, bowel function-1, urination problems-3 (frequency,
straining, activity limitation), and erectile dysfunction-1. **FACT-P consists of subscales
measuring: physical, functional, social, emotional, and prostate cancer-speciﬁc concerns.
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Methods of Step 2—Patient Interviews and
Practitioner Surveys
Patient interviews. A patient was considered eligible for this
study if he met all of the following inclusion criteria: 1) a rising
PSA while on hormonal therapy; 2) a castrate level of testoster-
one; and 3) experience of an anti-androgen withdrawal response
(i.e., regression of tumor associated with the suspension of anti-
androgen therapy). Additionally, the patient had to have at least
one of the following to be deemed eligible: a positive image on
bone or CT scan (i.e., an image indicative of neoplastic spread to
the bones), a rapid PSA doubling time, or a severely elevated PSA
(considered by the clinician to be indicative of HRPC). Patients
meeting these criteria were identiﬁed by their treating oncologist
(D.S.) who was caring for 45 HRPC patients during the three
month recruitment window. All were receiving treatment at
NorthShore University HealthSystem (Evanston, IL, USA). The
study was introduced by the oncologist during a regular
follow-up visit. Interested patients then met with a research
assistant for a more complete description of the study. To maxi-
mize the likelihood of thematic content saturation, we targeted a
sample size of 15 patients, a number consistent with current
recommendations for purposive samples for qualitative inter-
views [19]. The 15 patients who agreed to participate were
subsequently contacted to arrange a time and place for the inter-
view. No data were collected on patients who declined to par-
ticipate. Interviews were conducted between April and June,
2008 by the ﬁrst author (D.E.) who has prior experience con-
ducting one-on-one research interviews with prostate cancer
patients [20]. All patients were compensated $60 for their time.
The study was reviewed and approved by the Institutional
Review Board of NorthShore University HealthSystem (IRB No.
EH-08-209). All patients provided written informed consent
prior to the interview.
The patient interview was divided into an open and closed-
ended section. In the open-ended section, patients were ﬁrst
asked to reﬂect on their experience with advanced HRPC and to
identify the most important symptoms, complications, or con-
cerns to monitor when assessing the value of treatment for the
disease. Upon identifying each issue, patients were then asked to
rate the importance of the issue on a 0–10 scale (0 = not impor-
tant to 10 = extremely important). Following completion of the
open-ended section, patients were asked about the relevance and
importance of 26 additional issues. These included the following:
fatigue, nausea, vomiting, diarrhea, constipation, other bowel
problems (respondent speciﬁed), hair loss, breast enlargement,
infections, general pain, bone pain, peripheral neuropathy (tin-
gling in hands/feet), appetite loss, weight loss, urinary
obstruction/frequency, other urinary problems (respondent speci-
ﬁed), erectile dysfunction, other sexual problems (respondent
speciﬁed), masculine self-image, PSA anxiety, physical function,
emotional distress, functional well-being, social function, social
support, and global quality of life (QOL). These issues were
drawn from the step 1 literature review with some being further
speciﬁed or expanded. For instance, although not explicitly men-
tioned in the literature reviewed, PSA anxiety was included in the
interview protocol as a disease-speciﬁc marker of emotional dis-
tress. Furthermore, both social function (ability to participate in
social activities) and social support (existence of social relation-
ships and the assistance provided from these relationships) were
included in the protocol because they are domains often rolled
into scale and total scores from commonly used PRO measures
(e.g., the European Organization for Research and Treatment of
Cancer’s Quality of Life Questionnaire-Core 30 [EORTC QLQ-
C30] and the Functional Assessment of Cancer Therapy-Prostate
[FACT-P]). Finally, to account for the possibility of other urinary
complications besides frequency or obstruction and other sexual
complications besides erectile dysfunction, we included items
tapping “other urinary problems” and “other sexual problems”
and asked patients to specify. Brief deﬁnitions of the more general
domains of function (i.e., physical function, emotional distress,
functional well-being, social function, social support, and
global quality of life) were provided to patients prior to their
judgment of relevance and importance. These deﬁnitions were
informed by standard descriptions of these domains (see http://
www.nihpromis.org). They are provided in the appendix found
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i5_Eton.asp. For any concern endorsed as relevant,
patients were subsequently asked to rate it on the 0–10 impor-
tance scale. Demographic (i.e., age, race, education) and clinical
information (i.e., treatment, metastasis, PSA) were also collected
by patient query and medical chart review.
Practitioner surveys. A list of potential practitioner participants
was generated by the ﬁrst and last author (D.E. and D.C.). The
list represented all of the major medical specialties who treat or
care for advanced, HRPC patients (i.e., medical oncology, surgi-
cal oncology, radiation oncology, and nursing). Practitioners
were eligible if they reported having at least 3 years experience
treating or caring for at least 100 advanced HRPC patients. Most
of these practitioners were known to the authors from prior
collaborations. Others were suggested by contacted practitioners
who lacked sufﬁcient time to participate themselves. In total, 18
practitioners were invited. Four failed to respond to multiple
queries and another four declined citing lack of time. Self-report
surveys were electronically distributed to 10 practitioners. The
sample was purposively selected to provide diversity in discipline
(i.e., medicine, nursing), specialty (i.e., medical oncology, radia-
tion oncology, urology), and geographic region. We preferred the
survey format over interviews to facilitate timely data capture
from an experienced group of practitioners from different geo-
graphic regions. Completed surveys were returned to the ﬁrst
author (D.E.) and practitioners were compensated $60 for their
time.
The practitioner survey protocol was also divided into open
and closed-ended sections. Practitioners completed the open-
ended section ﬁrst, returned it, and were then sent the closed-
ended section to complete. In the open-ended section,
practitioners were ﬁrst asked to reﬂect upon their experience
Table 2 Major side effects or nonhematologic toxicities identiﬁed in
HRPC clinical studies (no. of times identiﬁed per treatment arm)
Side effect/toxicity Count
Fatigue 15
Nausea or vomiting 7
Alopecia 3
Gynecomastia 2
Infection 2
Pain 2
Bone pain 2
Diarrhea 2
Musculoskeletal tox. (unspeciﬁed) 1
Cardiovascular event 1
Dyspnea 1
Edema 1
Anorexia 1
Hand-foot syndrome 1
Injection site reaction 1
“Body as a whole” 1
Flushing 1
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treating HRPC and provide a list of the most important symp-
toms, complications, or concerns to monitor when assessing the
value of treatment for the disease. Like the patients, they also
rated the importance of each issue on their list using the 0–10
(not important to extremely important) scale. Finally, practitio-
ners were asked to judge whether each identiﬁed issue was more
likely a disease-related symptom, a treatment-related side effect,
both a symptom and side effect, or neither a symptom nor side
effect.
In the closed-ended section of the survey, practitioners were
asked to judge the relevance of the 26 issues identiﬁed in step 1.
For those issues endorsed as relevant to HRPC, two more deter-
minations were made. First, the practitioner was asked to rate the
importance of the issue on the 0–10 scale. Second, the practitio-
ner was asked to judge whether the endorsed issue was more
likely a disease-related symptom, a treatment-related side effect,
both a symptom and side effect, or neither a symptom nor side
effect. Practitioners also provided descriptive information about
themselves including age, gender, discipline, and specialty and
experience treating/caring for HRPC patients.
Results of Step 2
Patient interviews. Patients ranged in age from 50 to 93 years
with a median age of 72.8. Most were white/Caucasian (80%) or
white/Hispanic (13%). One African American man participated.
Most were college graduates (67%); however, a few (20%) had
no more than a high school education. Most were also married
(87%) and retired (67%). Clinical characteristics appear in
Table 3. All patients had metastatic prostate cancer and most had
evidence of disease progression (rising PSA) at the time of the
interview. Notably, PSA had stabilized for several men by the
time of the interview, likely resulting from ongoing treatment for
their malignancy. Most patients (80%) rated themselves as being
symptomatic according to Eastern Cooperative Oncology Group
criteria. Patients were receiving a variety of treatments including
chemotherapy, hormonal therapy (e.g., leuprolide, bicalutamide,
goserelin), and bisphosphonate therapy.
Patients identiﬁed a total of 38 complications in the open-
ended portion of the interview. Overall, minimal coding of
responses was necessary because, in most instances, the patients’
verbatim responses were used. In the few instances where mul-
tiple responses seemed to reﬂect a common underlying concern,
two of the authors (D.E. and D.C.) discussed and agreed upon a
single name for the concern (e.g., “fatigue” and “tiredness” were
named “fatigue”). We checked for thematic content saturation in
the following manner. First, responses from the ﬁrst 12 inter-
views were summarized. Next, patient responses from the last
three interviews were compared with the results of the ﬁrst 12
interviews to determine whether any new themes (i.e., outcome
issues) emerged. An additional four issues emerged in the ﬁnal
three interviews (11% of the total number of issues provided by
patients). Two of these four issues were already represented in the
closed-ended portion of the interview. Hence, there was sufﬁcient
evidence to conclude that saturation had been reached after 15
interviews.
The 38 complications were entered into a table showing the
frequency of endorsement of each along with its mean impor-
tance rating. Two rules were articulated to select eligible compli-
cations for inclusion in a preliminary version of the conceptual
framework. A complication was selected if, 1) it was recalled by
more than one patient; and 2) it had a mean importance rating of
at least 5.0 (i.e., moderately important). Table 4 displays the
eight complications that met these inclusion rules (note: data on
all 38 complications are available from the ﬁrst author).
Judgments of the 26 issues reviewed by patients in the closed-
ended portion of the interview were also entered into a data table
of frequency and mean importance. Two rules were articulated to
select eligible complications or QOL concerns for inclusion in the
preliminary version of the conceptual framework. A complica-
tion was selected if, 1) >50% of patients endorsed it as a concern
of HRPC (regardless of the mean importance score); or 2) >25%
of patients endorsed it as a concern of HRPC and it had a mean
importance rating of at least 5.0 (moderately important). These
selection thresholds are slightly more restrictive than those used
Table 3 Patient clinical characteristics
Most recent PSA Median = 23.12 ng/mL
Range: 1.78 to 335.00 ng/mL
(note: Data missing from 2 patients)
PSA rising at time of interview? Yes 9 (60%)
No 6 (40%)
Metastasis? Yes 15 (100%)
No 0 (0%)
Patient-reported performance status
(Eastern Cooperative Oncology Group: ECOG)
ECOG 1 (some symptoms, no bed rest during day) 9 (60%)
ECOG 0 (normal activity) 3 (20%)
ECOG 2 (req. bed rest < 50% of waking day) 3 (20%)
Current or past 6 month chemotherapy? Yes 10 (67%)
No 5 (33%)
Current or past 6 month radiotherapy? Yes 4 (27%)
No 11 (73%)
Hormone therapy in past month? Yes 12 (80%)
No 3 (20%)
Bisphosphonate therapy in past month? Yes 12 (80%)
No 3 (20%)
Table 4 Complications identiﬁed in open-ended section of patient
interview and eligible for inclusion in the preliminary framework
Complication
Frequency of
endorsement
Mean importance
rating
Fatigue 9 7.44
General pain 3 6.00
Leg muscle soreness/weakness 3 5.67
Cognitive decline/memory loss 2 9.00
PSA anxiety 2 8.50
Diarrhea 2 7.50
Bone pain 2 6.50
Disrupted taste sensation 2 6.00
Note. Importance rated from 0 (not important) to 10 (extremely important).
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for the open-ended complications because recognition is less
cognitively challenging than recall. Table 5 displays the sixteen
complications that met one of the inclusion rules (note: data on
all 26 complications are available from the ﬁrst author).
Combining results from the open- and closed-ended portions
of the patient interview yielded a total of 19 unique outcome
issues to serve as candidates for inclusion in the preliminary
conceptual framework. Note that ﬁve of these selected issues
appeared in both portions of the interview. Results from the
practitioner surveys were next used to fully outline a preliminary
version of the conceptual framework.
Practitioner surveys. Eight physicians (all male) and two nurses
(both female) submitted completed surveys. The physicians rep-
resented the specialties of medical oncology (5), urology (2), and
radiation oncology (1); one nurse worked in medical oncology,
the other worked in urology. Geographically, six practitioners
were based in the United States (three Midwest, two East Coast,
one Mid-Atlantic), two were based in Australia, one was based in
Canada, and another was based in Europe. Median age of the
practitioners was 46.0 years (range 39–56 years). Most (70%)
had already treated or cared for at least 500 HRPC patients and
almost all (90%) had been treating or caring for HRPC patients
for over 5 years.
In developing the PRO conceptual framework, we relied prin-
cipally upon patient input, with support provided by practitioner
input. Data from the practitioners were not used to elucidate any
new outcome issues for inclusion in the framework, rather they
were used to clinically verify and categorize the outcome issues
already identiﬁed by HRPC patients as relevant. The 19 patient-
endorsed candidate outcome issues were subjected to a clinical
veriﬁcation procedure using the data from the practitioner
surveys. An outcome issue was considered “clinically veriﬁed” if
more than 25% of practitioners endorsed it as relevant in either
the open- or closed-ended section of the survey. Table 6 shows
that 16 of the 19 patient-endorsed issues were veriﬁed by prac-
titioners as being relevant to HRPC. Practitioners were also
asked to make a judgment regarding the etiology of any disease-
related issue that they endorsed. Response options included: 1)
exclusively a disease symptom; 2) exclusively a treatment side
effect; 3) both a symptom and side effect; or 4) neither a
symptom nor side effect. The etiologic classiﬁcation was deter-
mined by the vote of the majority of practitioners. Results are
shown in the rightmost column of Table 6. Note that this judg-
ment was not made for general QOL issues because general
domains of QOL can be determined by multiple factors.
Preliminary version of the conceptual framework. Our prelimi-
nary version of a conceptual framework of PROs for metastatic
HRPC features 16 outcome issues classiﬁed into ﬁve broad cat-
egories. These include the following: 1) speciﬁc symptoms of
disease (overall pain, bone pain, urinary obstruction/frequency);
2) speciﬁc physical side effects of treatment (constipation, erectile
dysfunction, peripheral neuropathy, diarrhea); 3) physical symp-
toms of disease and side effects of treatment (fatigue, appetite
loss); 4) speciﬁc psychological concerns (PSA anxiety, change in
self-image); and 5) general QOL and well-being (physical func-
tion, functional well-being, social function, emotional distress,
global QOL). In step 3, we used quantitative analyses of archived
PRO data to conﬁrm and/or modify the preliminary framework
into a ﬁnal conceptual framework of PROs in metastatic HRPC.
Methods of Step 3—Analyses of Archived Data
We had available to us PRO data from a Phase III clinical trial of
HRPC. Conducted in the early 1990s, this two-arm trial com-
pared the palliative effects of mitoxantrone chemotherapy with
prednisone to prednisone alone [21]. The dataset was particu-
larly useful as it contained individual item-level responses on two
PRO instruments, the Prostate Cancer-Quality of Life Instrument
(PROSQOLI) and the Quality of Life Module-Prostate 14
(QOLM-P14) [22]. Collectively, these instruments represented
many of the issues identiﬁed in our preliminary conceptual
framework as well as a few issues not in the current version of the
framework. This allowed us to test the ﬁtness of the current
Table 5 Complications/quality of life issues rated in the closed-ended
section of the patient interview and eligible for inclusion in the preliminary
framework
Complication or QOL concern
Frequency of
endorsement (%)
Mean importance
rating
PSA anxiety 15 (100%) 8.0
Fatigue 15 (100%) 6.5
Physical function 11 (73%) 7.2
Emotional distress 10 (67%) 6.9
Urinary problems (increased
frequency, straining)
9 (60%) 6.7
Global QOL 9 (60%) 6.4
Constipation 9 (60%) 4.8
Functional well-being 8 (53%) 6.1
Erectile dysfunction 8 (53%) 5.6
Bone pain 7 (47%) 6.6
Peripheral neuropathy (tingling in
hands or feet)
7 (47%) 5.7
General pain 7 (47%) 5.0
Diarrhea 6 (40%) 6.2
Masculine self-image 5 (33%) 7.4
Social function 5 (33%) 5.6
Appetite loss 4 (27%) 7.8
Note. Importance rated from 0 (not important) to 10 (extremely important).
Table 6 Practitioner veriﬁcation and etiologic classiﬁcation of patient-
endorsed concerns
Speciﬁc-disease related concern
Practitioner
veriﬁed?* Etiology†
Overall pain Yes Exclusively symptom
Bone pain Yes Exclusively symptom
Urinary problems
(obstruction/frequency)
Yes Exclusively symptom
Constipation Yes Exclusively side effect
Erectile dysfunction Yes Exclusively side effect
Peripheral neuropathy Yes Exclusively side effect
Diarrhea Yes Exclusively side effect
Masculine self-image Yes Exclusively side effect
Fatigue Yes Both symptom & side effect
Appetite loss Yes Both symptom & side effect
PSA Anxiety Yes Both symptom & side effect
Leg muscle soreness/weakness No N/A
Cognitive decline/memory loss No N/A
Disrupted taste sensation No N/A
General QOL concern
Practitioner
veriﬁed? Etiology
Physical function Yes N/A
Emotional distress Yes N/A
Global quality of life Yes N/A
Functional well-being Yes N/A
Social function Yes N/A
*A concern is clinically veriﬁed if it is endorsed by more than 25% of practitioners in either
the open- or closed-ended section of the survey. †Etiology determined by the majority vote
of practitioners. Possible responses included: (1) Exclusively symptom of disease (2) Exclu-
sively side effect of treatment (3) Both a symptom of disease and side effect of treatment (4)
Neither a symptom of disease nor side effect of treatment.
N/A, not applicable.
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version of the framework (i.e., conﬁrmation) and to potentially
augment the framework with issues un-represented in the current
version (i.e., modiﬁcation). Approval to analyze these data was
granted by the trial’s principal investigator (Ian Tannock, MD).
Patients and procedure. One hundred sixty-one advanced HRPC
patients participated in the trial comparing mitoxantrone +
prednisone (n = 80) to prednisone alone (n = 81). All had docu-
mented metastases, were symptomatic, and had progressing
disease despite standard hormonal therapy [21]. Patients ran-
domized to the mitoxantrone arm received it intravenously every
3 weeks. All patients received oral prednisone at a dosage of
10 mg/day. Patients were examined clinically every 3 weeks at
which time they completed the PROSQOLI and QOLM-P14
(note: the ﬁrst or “baseline” assessment occurred at the outset of
the ﬁrst cycle of treatment). The PROSQOLI consists of nine
linear analog self-assessment scales that relate to pain, physical
activity, fatigue, appetite, constipation, urinary problems, family/
marriage relationships, mood, and overall well-being. Each scale
consists of a 100-mm line with anchors on the left (0) indicating
poorest function/most symptomatic and the right (100) indicat-
ing best function/least symptomatic. A score of 50 is indicative of
moderate function/symptomatology. The QOLM-P14, a prostate
cancer-speciﬁc module developed according to guidelines of the
EORTC, assesses pain, hair loss, disrupted taste sensation,
fatigue, cognitive dysfunction, and urinary problems. Each of the
14 items is rated on a four-point ordinal scale (1-not at all, 2-a
little, 3-quite a bit, 4-very much) with a higher score indicative of
worse function/more of the symptom.
Baseline endorsement frequencies of the PROSQOLI and
QOLM-P14 items were ﬁrst determined. This allowed identiﬁ-
cation of problems occurring prior to the administration of any
study treatments, ostensibly identifying disease symptoms as
opposed to treatment side effects. We paid particular attention
to those items endorsed as “moderately” to “severely” prob-
lematic by at least a third (33%) of patients. Moderately to
severely problematic is deﬁned here as a score of 50 on any
PROSQOLI item and a rating of either “quite a bit” or “very
much” on any QOLM-P14 item. We also plotted prospective
mean scores for each item by treatment group to help determine
whether these problems and concerns change with treatment.
Area under the curve (AUC) analysis was used to compare the
prospective item-level scores across treatment group. Speciﬁ-
cally, the AUC was calculated for the ith individual using a
trapezoidal approximation:
AUC t t
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where Yij indicates the item score and tj indicates the time (cycle).
To minimize bias due to missing data, we plotted scores for the
ﬁrst seven cycles only. By cycle 7, nearly 50% of patients had
missing PRO data. For those patients dropping out prior to cycle
7, their worst observed score was assigned for all subsequent
assessments in the AUC calculation. For intermittent missing
data, linear interpolation was used to impute the missing value.
The mean AUC was compared across the two treatment arms
using two-sample t-tests.
Results of Step 3
Six of the nine PROSQOLI items were scored moderately to
severely problematic by at least 33% of all patients at baseline.
These included the following items: fatigue (61%), constipation
(43%), pain (42%), overall well-being (36%), appetite loss
(36%), and physical activity (33%). Furthermore, six of the 14
QOLM-P14 items were rated moderately to severely problematic
by at least 33% of patients at baseline. These included the
following items: taking medicine for pain (73%), feeling pain
during physical activity (54%), pain interfering with social activi-
ties (48%), urination interfering with sleep (37%), pain interfer-
ing with family activities (37%), and pain while sitting or lying
down (34%). Most of the outcome issues being addressed by
these items are already a part of the preliminary conceptual
framework. Hence, the baseline trial data conﬁrm many aspects
of the preliminary framework. One issue, taking medicine for
pain, although not explicitly delineated within the framework, is
subsumed within the domain of overall pain.
Results of the AUC analyses comparing prospective scores of
the PROSQOLI and QOLM-P14 items across treatment group
are shown in Table 7. There were no signiﬁcant differences on
any of the PROSQOLI items. However, the treatment groups did
signiﬁcantly differ on ﬁve items from the QOLM-P14: pain
during physical activity (P = 0.03), pain while sitting or lying
down (P = 0.03), pain remaining after taking medication
(P = 0.003), upset by hair loss (P = 0.003), and bother about
changes in taste sensation (P = 0.004). The corresponding curves
of these items appear in Figure 2a–e. As Figure 2a–c show, pain
appears to decline substantially more over the course of treat-
ment with mitoxantrone chemotherapy than with prednisone
alone. This further conﬁrms the importance of a pain domain
within the conceptual framework. The ﬁndings for hair loss and
changes in taste sensation (Fig. 2d,e) provide evidence supportive
of a modiﬁcation in the preliminary framework. Patients treated
with mitoxantrone chemotherapy became increasingly distressed
by these problems over the course of treatment, more so than
patients treated with prednisone alone.
Proposing a Final Conceptual Framework of PROs
in HRPC
The ﬁnal version of the conceptual framework of PROs in meta-
static HRPC appears in Figure 3. It consists of the 16 outcome
issues derived from the patient and practitioner queries, many of
which were also conﬁrmed by analyses of an archived dataset, as
well as two additional issues determined to be relevant through
the analyses of the archived patient data. Given that both hair
loss and changes in taste sensation appeared to manifest after
treatment with chemotherapy, they are classiﬁed as physical side
effects of treatment in the ﬁnal model.
Discussion
We used a combination of qualitative and quantitative methods
to derive a conceptual framework of PROs for metastatic HRPC.
Our ﬁnal model included 18 outcome issues categorized into ﬁve
general content domains, 1) speciﬁc physical symptoms of
disease; 2) speciﬁc physical side effects of treatment; 3) physical
symptoms of disease and side effects of treatment; 4) speciﬁc
psychological concerns; and 5) general aspects of QOL and well-
being. Though our study samples were small, they were not
unrepresentative. Like most HRPC patients, most of the men in
our study were symptomatic, had high and rising PSA levels, and
were receiving a variety of treatments to control their disease
including hormonal ablation, chemotherapy, and bisphospho-
nate therapy. Furthermore, the practitioners queried all had con-
siderable experience caring for and treating HRPC patients, and
were representative of all of the major medical specialties that
treat HRPC. This coupled with the insights provided by analyses
of a larger dataset of HRPC patients lends conﬁdence in the
robustness of our proposed framework.
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A conceptual framework helps to specify the most important
outcomes of interest in a given disease population. Pragmati-
cally, it can be used to guide the development of an assessment
strategy. In instances where existing outcome measures are
lacking, the framework provides the supportive rationale for
creating a new outcome measure. However, in contexts where
suitable outcome measures already exist, the framework is no
less useful as it can be used to select from among available
instruments. In HRPC, standardized assessments of many of the
outcomes featured in the ﬁnal framework already exist. For
example, the EORTC and FACT measurement systems offer
general core instruments and prostate-cancer-speciﬁc modules
that address most of the issues outlined in the framework. Fur-
thermore, side effects of treatment can be efﬁciently captured
using standard adverse event criteria, which can be either
clinician- or patient-reported [23,24]. The decision to either use
existing measures or create a new measure will depend upon the
outcomes that are most salient to a given study as well as the
relevance and quality of any existing measures. When relevant
and high-quality measures are already available, as they would
seem to be in this disease context, then creation of a new
measure may be unnecessary.
Two other useful models are informed by the conceptual
framework. A conceptual model of outcomes can provide a
broader theoretical understanding of the disease and treatment
process. Whereas the conceptual framework speciﬁes a broad
taxonomy of patient-focused outcomes relevant to a given
disease or health condition, a conceptual model goes one step
further by proposing causal linkages and relationships among
these outcomes. Generic as well as disease-speciﬁc conceptual
models have been proposed by others [5,6,25,26]. Such models
are valuable as they can help clarify the expected impacts of a
disease and its treatment on patient well-being. This can facilitate
hypothesis generation and may even pinpoint targets for inter-
vention. Although it is possible to hypothesize a conceptual
model from our data, it is best considered preliminary, given the
limits imposed by the small sample size and the collection of data
at a single time point.
A second model potentially informed by this conceptual
framework is an end point model one might conceive for a new
clinical trial. Such a model shows the relationships across clini-
cal, patient-reported, and other end points, and has relevance to
investigators working in a regulatory approval context [4]. A
sample end point model for a hypothetical treatment for HRPC
is shown in Figure 4. Such models are the theoretical basis for the
intervention and therefore provide the foundation on which a
desired labeling claim rests.
Our study is not without limitations. First, as noted, we
conducted semistructured qualitative interviews on a relatively
small sample of patients. Interviewing more patients might have
resulted in a different framework, though recent evidence sug-
gests that as few as 12 interviews are enough to achieve satura-
tion in thematic content [19]. Notably, we found that 89% of the
outcome issues identiﬁed in the open-ended portion of the inter-
view were reﬂected in the ﬁrst 12 patient interviews. In the last
three patient interviews, only four new outcome issues arose two
of which were also queried in the closed-ended portion of the
interview. Second, it is possible that the use of a different quali-
tative method such as focus groups would have produced differ-
ent results. We chose the interview format for pragmatic reasons.
One-on-one interviews were easier to schedule either before or
after a routine clinic visit or in some cases between visits in the
patient’s home. Furthermore, we felt that some of the more
symptomatic men would have greater difﬁculty traveling to a
separate group session and therefore might be less inclined to
participate. Third, diversity in the patient sample was limited by
recruitment at a single clinical site in the midwestern United
States with less representation of patients from racial and ethnic
minority groups. Finally, although the conﬁrmatory statistical
analyses were a strength of our study, we had access to only one
Table 7 Area under the curve analyses of PRO data from the mitoxantrone trial in HRPC
PROSQOLI
M + P* P*
P-valueN Mean (SD) N Mean (SD)
Pain 79 433 (162) 76 400 (152) 0.190
Physical Activity 79 451 (142) 76 436 (134) 0.498
Fatigue 79 347 (151) 76 339 (156) 0.743
Appetite 79 452 (164) 76 455 (191) 0.909
Constipation 79 403 (160) 76 421 (189) 0.522
Relationships 79 587 (129) 76 587 (120) 0.997
Mood 79 472 (148) 76 471 (146) 0.948
Urination† 50 552 (143) 47 522 (176) 0.359
Well-being 79 435 (144) 76 426 (148) 0.700
QOLM-P14 N Mean (SD) N Mean (SD)
Pain during physical activity 79 14.8 (4.8) 76 16.5 (5.0) 0.030
Pain while sitting or lying down 79 13.0 (4.1) 76 14.6 (5.6) 0.033
Pain wakes you up at night 79 11.1 (3.8) 76 12.1 (4.7) 0.145
Pain interferes with enjoyment of family 79 11.9 (4.6) 76 12.7 (5.3) 0.327
Pain interferes with social activity 79 13.1 (4.6) 76 14.0 (5.9) 0.301
Upset by hair loss 79 8.5 (3.0) 74 7.4 (1.2) 0.003
Bothered by changes in taste 79 11.7 (4.3) 76 9.8 (3.5) 0.004
Felt drowsy 79 13.4 (4.5) 76 14.1 (5.1) 0.375
Felt confused 79 9.9 (3.6) 76 10.0 (3.7) 0.846
Taking medication for pain 79 18.0 (4.6) 76 18.8 (5.5) 0.358
Pain remained after taking medication 78 11.2 (3.0) 75 12.9 (4.1) 0.003
Dissatisﬁed with pain relief 79 10.0 (3.1) 75 10.5 (4.2) 0.398
Getting up at night to pass urine† 52 8.8 (2.7) 48 9.6 (4.0) 0.263
Nightly urination interfered with sleep† 52 14.1 (4.2) 48 14.6 (5.4) 0.572
*M + P =mitoxantrone + prednisone. P = prednisone alone. †Items reﬂecting urinary problems were added midway through the trial. PROSQOLI: Prostate Cancer Quality of Life Instrument.
QOLM-P14: Quality of Life Module-Prostate 14.
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Figure 2 (a) Pain during physical activity: Mean scores with 95% conﬁ-
dence intervals (higher score =more pain). P = prednisone only,
M + P =mitoxantrone + prednisone. (Note: The ﬁrst assessment [base-
line] occurred at the outset of cycle 1) (b) Pain while sitting or lying
down: Mean scores with 95% conﬁdence intervals (higher score =more
pain). P = prednisone only, M + P =mitoxantrone + prednisone. (Note:
The ﬁrst assessment [baseline] occurred at the outset of cycle 1). (c) Pain
remaining after taking medication: Mean scores with 95% conﬁdence
intervals (higher score =more pain). P = prednisone only, M + P =
mitoxantrone + prednisone. (Note: The ﬁrst assessment [baseline]
occurred at the outset of cycle 1). (d) Upset by hair loss: Mean
scores with 95% conﬁdence intervals (higher score =more upset).
P = prednisone only, M + P =mitoxantrone + prednisone. (Note:The ﬁrst
assessment [baseline] occurred at the outset of cycle 1). (e) Bothered by
changes in taste: Mean scores with 95% conﬁdence intervals (higher
score =more bother). P = prednisone only, M + P =mitoxantrone +
prednisone. (Note:The ﬁrst assessment [baseline] occurred at the outset
of cycle 1).
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archived dataset of HRPC patients treated with a limited number
of therapies. Availability of more item-level PRO data from a
greater number of instruments and representing a wider range of
treatments could have led to slightly different conclusions about
the framework.
Conclusion
We have developed a conceptual framework of salient, patient-
relevant outcome issues for metastatic HRPC. It identiﬁes several
critical target areas for assessment including, disease symptoms,
treatment side effects, psychological concerns, and general
aspects of QOL. The framework can help guide investigators in
the selection of outcomes and may even help pinpoint areas
suitable for intervention. Although it may be revised as new data
are made available and new therapeutics are discovered, this
initial version can serve as the basis from which future concep-
tual frameworks and models can be derived.
Source of ﬁnancial support: Study supported by Bayer Schering Pharma
AG.
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